Ultragenyx Pharmaceutical Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on February 21, 2018, by Ultragenyx Pharmaceutical Inc. The report addresses the acquisition of Dimension Therapeutics, Inc., which was completed on November 7, 2017. The filing provides unaudited pro forma condensed combined financial information for the year ended December 31, 2017, reflecting the impact of this acquisition.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references the existence of an "unaudited pro forma condensed combined statement of operations" attached as Exhibit 99.1, but the actual figures are not included in the provided text.
Material Changes
The primary material change reported is the acquisition of Dimension Therapeutics, Inc. The pro forma financial statements are presented to show the combined entity's performance for the 2017 fiscal year as if the acquisition had occurred at the beginning of the period.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies beyond the disclosure of the acquisition and the attached pro forma data.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific unaudited pro forma revenue and net loss figures for the year ended December 31, 2017.
- Verify the accounting treatment and integration costs associated with the Dimension Therapeutics acquisition.
- Confirm the impact of the acquisition on the company's cash position and debt obligations as detailed in the full pro forma statement.